Evidence map›Paper›PMID 37264079›Full record

ArticleNature2023

Publisher Correction: Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.

Joon Seok Park, Francesca S Gazzaniga, Meng Wu, Amalia K Luthens, Jacob Gillis, Wen Zheng, Martin W LaFleur, Sarah B Johnson, Golnaz Morad, Elizabeth M Park and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Joon Seok Park *Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4001-6886
Francesca S Gazzaniga *Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Meng WuDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Amalia K LuthensDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2179-712X
Jacob GillisDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Wen ZhengDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Martin W LaFleurDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Sarah B JohnsonProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8936-0958
Golnaz MoradProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-9460-618X
Elizabeth M ParkProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yifan ZhouProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Stephanie S WatowichProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1969-659X
Jennifer A WargoProgram for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3438-7576
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. gordon_freeman@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-7210-5616
Dennis L KasperDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. dennis_kasper@hms.harvard.edu.ORCID http://orcid.org/0000-0001-8808-5333
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. arlene_sharpe@hms.harvard.edu.ORCID http://orcid.org/0000-0002-9736-2109

Funding

Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI ASTER, JON C. · 2017 to 2021
$10.6M
Elucidating the role of gut, blood, and tumor microbiota in brain metastasisF32CA260769 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MORAD, GOLNAZ · 2021 to 2023
$205k
NCI NIH HHS F32 CA260769NCI NIH HHS P50 CA206963NIAID NIH HHS P01 AI056299
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37264079
PMCPMC12025598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.